Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

Area of Science:

• Molecular Biology
• Pharmacology
• Oncology

Background:

• The BCL-2 gene plays a crucial role in cell survival and is often dysregulated in various cancers.
• Targeting specific gene sequences offers a potential therapeutic strategy for cancer treatment.
• Developing effective delivery systems is essential for oligonucleotide-based therapies.

Purpose of the Study:

• To evaluate the antitumor activity and specificity of PNT2258, a liposomal formulation of the DNA oligonucleotide PNT100.
• To assess the efficacy of PNT2258 against BCL-2-driven and other resistant cancer xenografts.
• To investigate the mechanism of action, DNA interference, mediated by PNT100.

Main Methods:

• PNT100, a 24-base DNA oligonucleotide targeting BCL-2, was encapsulated in amphoteric liposomes to create PNT2258.
• In vitro and in vivo studies were conducted using various cancer xenografts, including lymphoma, melanoma, and prostate cancer.
• Sequence specificity was confirmed using control oligonucleotides with identical formulation and particle characteristics.

Main Results:

• PNT2258 demonstrated significant antitumor activity against BCL-2-driven lymphoma, resistant melanoma, prostate, and Burkitt's lymphoma xenografts.
• The DNA interference mechanism led to suppressed proliferation and cell death in tumor cells exposed to PNT100.
• Control sequences showed no antiproliferative activity, confirming the sequence-specific efficacy of PNT100.

Conclusions:

• PNT2258 exhibits broad-spectrum antitumor activity and favorable pharmacokinetic properties due to its liposomal encapsulation.
• The sequence-specific DNA interference mechanism provides a targeted approach to cancer therapy.
• PNT2258 is currently in clinical trials for recurrent or refractory non-Hodgkin's lymphoma, indicating its therapeutic potential.